Ronac Mamtani
Overview
Explore the profile of Ronac Mamtani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
166
Citations
3719
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stalker M, Qu K, Cohen R, Mamtani R, Hwang W, Sun L
J Natl Compr Canc Netw
. 2025 Feb;
23(3):90-96.
PMID: 39933487
Background: The KEYNOTE-048 study established the checkpoint inhibitor (CPI) pembrolizumab, with/without chemotherapy, as frontline treatment for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). However, pembrolizumab monotherapy has limited...
2.
Wang X, Gimotty P, Matthews A, Mamtani R, Luger S, Hexner E, et al.
Blood Adv
. 2025 Jan;
9(3):533-544.
PMID: 39888631
Little is known about the impact of recent advances in acute myeloid leukemia (AML) treatment on racial/ethnic disparities in survival outcomes. We performed a retrospective cohort study of patients with...
3.
Orcutt X, Chen K, Mamtani R, Long Q, Parikh R
Nat Med
. 2025 Jan;
31(2):457-465.
PMID: 39753967
Randomized controlled trials (RCTs) evaluating anti-cancer agents often lack generalizability to real-world oncology patients. Although restrictive eligibility criteria contribute to this issue, the role of selection bias related to prognostic...
4.
Reibel J, Sun L, Parikh R, Mahmud N, Martin L, Hubbard R, et al.
J Natl Cancer Inst
. 2024 Dec;
PMID: 39658317
The recent cisplatin and carboplatin ("platinum") chemotherapy shortage, first announced on February 10, 2023, has impacted cancer patients nationwide. Here, we quantify the extent to which the shortage affected platinum...
5.
Mamtani R, Matsubara N, Pino A, Herranz U, Sendur M, Gravis G, et al.
Clin Genitourin Cancer
. 2024 Nov;
23(1):102248.
PMID: 39579409
Introduction: The phase 3 KEYNOTE-361 trial of first-line pembrolizumab with or without chemotherapy versus chemotherapy alone in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) completed enrollment before the...
6.
Flechon A, Morales-Barrera R, Powles T, Alva A, Ozguroglu M, Csoszi T, et al.
Clin Cancer Res
. 2024 Oct;
30(23):5353-5364.
PMID: 39475359
Purpose: The three-arm, phase III KEYNOTE-361 study did not meet its dual primary endpoints of progression-free survival (PFS) or overall survival (OS) with first-line pembrolizumab plus chemotherapy versus chemotherapy in...
7.
Barsouk A, Elghawy O, Yang A, Sussman J, Mamtani R, Mei L
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39409958
Background: Urothelial carcinoma (UC) is one of the most common cancers diagnosed worldwide. However, minority populations, such as female, elder, and Black patients, may have disparate outcomes and are commonly...
8.
Guadamuz J, Wang X, Altomare I, Camelo Castillo W, Sarkar S, Mamtani R, et al.
JNCI Cancer Spectr
. 2024 Sep;
8(5).
PMID: 39271476
Background: Although racially and ethnically minoritized populations are less likely to participate in cancer trials, it is unknown whether social determinants of health (SDOH) explain these inequities. Here we identify...
9.
Mamtani R, Ulloa-Perez E, Parikh R, Patel K, Moreno B, Ramamurthy C, et al.
Eur Urol
. 2024 Aug;
86(5):474-476.
PMID: 39174408
No abstract available.
10.
Brown T, Gimotty P, Mamtani R, Karasic T, Yang Y
JCO Clin Cancer Inform
. 2024 Aug;
8:e2300220.
PMID: 39088775
Purpose: Systemic therapy with atezolizumab and bevacizumab can extend life for patients with advanced hepatocellular carcinoma (HCC). However, there is substantial variability in response to therapy and overall survival. Although...